Dong-A, Green Cross likely immune to financial crisis

Chances are looming larger that a majority of pharmaceutical firms, except for Dong-A Pharmaceutical and Green Cross Crop., will face a blow for their revenues as the government’s new drug pricing initiative could not only slash their sales and operating profits by 20 percent but push many marginal companies out of business.

However, Dong-A saw its third-quarter sales of Bacchus drink to pha...